Mail Us

contact@liqomics.com

Call Us

(+49) 221 69 056 597

Exciting Updates for the Hematology and Oncology Community

Blog
Minimal Residual Disease In Hodgkin Lymphoma

Exciting Updates for the Hematology and Oncology Community – Minimal Residual Disease in Hodgkin Lymphoma

We’re thrilled that next week, from October 26-28, 2024, the highly anticipated 13th International Symposium on Hodgkin Lymphoma (ISHL 13) will take place in Cologne. This world-renowned event brings together leading experts, researchers, and clinicians in the field of hematology and oncology, all united in the fight against Hodgkin Lymphoma. As a key player in this space, we at Liqomics are excited to contribute to the discussions that will shape the future of lymphoma research and treatment.

Focus on Minimal Residual Disease (MRD) in Hodgkin Lymphoma

Our focus at ISHL 13 is on a groundbreaking topic that holds immense potential for cancer treatment: Minimal Residual Disease (MRD) in Hodgkin Lymphoma. MRD detection is essential for understanding how much cancer remains after treatment, playing a pivotal role in preventing relapse and guiding patient-specific therapies.

At ISHL 13, we’re proud to present new validation data for the state-of-the-art MRD detection test LymphoVista HL, marketed by Liqomics. This breakthrough technology offers clinicians unparalleled accuracy in detecting minimal residual disease in Hodgkin Lymphoma patients. LymphoVista HL delivers precise insights that help clinicians make informed, personalized treatment decisions—aiming to ultimately improve patient outcomes and reduce the risk of relapse.

Why LymphoVista HL Matters

As the standard of care in lymphoma treatment continues to evolve, the ability to detect MRD with precision is becoming a cornerstone of effective long-term cancer management. There are many possibilities how LymphoVista HL can be used in the future to improve Hodgkin Lymphoma care:

  • Enhance precision in treatment monitoring by detecting even the smallest traces of cancer that may be missed by traditional diagnostic methods.
  • Personalize treatment strategies based on each patient’s unique MRD profile, enabling more effective, targeted therapies.
  • Improve patient outcomes by reducing the chances of relapse through timely intervention, ensuring that treatments are as effective as possible.

 

Join Us at ISHL 13

If you’re attending ISHL 13, we invite you to talk to us to learn more about how MRD and LymphoVista HL are driving innovation in the monitoring and treatment of Hodgkin Lymphoma. This is a unique opportunity to connect with global thought leaders, researchers, and clinicians who are dedicated to improving outcomes for lymphoma patients. Sven Borchmann MD/PhD, managing director of Liqomics, will be available to discuss the latest advancements in MRD technology and share insights from our new validation data.

We look forward to engaging with you and contributing to important discussions that are shaping the future of lymphoma research and personalized oncology care.

Stay Tuned for More

We’ll be sharing more updates soon. Be sure to follow our progress as we continue to advance cancer treatment by optimal disease monitoring.

We look forward to seeing you at ISHL 13!

Tag Post :
Share This :